NRS Webinar-New treatment implications
NRS Webinar-"New Treatment Implications" 6 February 12:30-13:30
Invited speakers
Dr. Emily van ‘t Wout “Novel state-of-the art treatment implications and strategies in AATD”
Prof. Marlies Wijsenbeek “Current insights into the pharmacological treatment of pulmonary fibrosis and a look toward the future”
Dr. Emily F.A. van ‘t Wout, MD Ph.D. is an Assistant Professor at the Department of Pulmonology at the Leiden University Medical Center in the Netherlands. She is a renowned expert in Alpha-1 Antitrypsin Deficiency (AATD) in the Netherlands and beyond. Her groundbreaking PhD work in AATD included the first successful culture of differentiated primary airway epithelial cells from AATD patients and identification of a key inflammatory pathway linked to the disease. In her current role, she is focused on advancing AATD-related emphysema research and translating findings into potential curative treatments as both translational as well as clinical scientist. Dr. Emily F.A. van ‘t Wout recently received both the Starting Grant (LUMC) as well as the prestigious Clinical Fellow (ZonMW) to study polymers in the lungs and their role in repair processes. As one of the national leaders in AATD research, she has fostered international collaborations, including with top institutions like University College London and the University of Cambridge. She contributes to the Dutch AATD expertise center, recognized by the European Reference Network (ERN)-LUNG, led national and international webinars, and co-chairs the AATD core network of ERN-LUNG.
Prof. Marlies Wijsenbeek is a professor of interstitial lung diseases and a pulmonologist at Erasmus Medical Center in Rotterdam. She leads a variety of clinical studies aimed at improving the diagnosis, treatment, and care for patients with pulmonary fibrosis and sarcoidosis. She is a strong advocate for personalized and patient-centered care. Also, she is deeply involved in education through European training programs on interstitial lung diseases. In this webinar, she will share valuable insights into the latest developments in the pharmacological treatment of pulmonary fibrosis.
